お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
968791

インターフェロンベータ薬の世界市場 - 製品種類別・投与経路別・流通チャネル別・地域別:市場規模・シェア・将来展望・機会分析

Interferon Beta Drugs Market, by Product Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 169 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
インターフェロンベータ薬の世界市場 - 製品種類別・投与経路別・流通チャネル別・地域別:市場規模・シェア・将来展望・機会分析
出版日: 2020年10月19日
発行: Coherent Market Insights
ページ情報: 英文 169 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

現在、世界各国で多発性硬化症の有病者が増加し続けており、それがインターフェロンベータ薬の主な市場促進要因となっています。

当レポートでは、世界のインターフェロンβ薬の市場について分析し、製品の概要や背景事情、市場の基本構造および促進・抑制要因、全体的な市場規模の見通し (金額ベース、過去4年間・今後8年間分)、製品種類別・投与経路別・流通チャネル別・地域別の詳細動向、主要企業のプロファイル・業績・戦略計画などを調査しております。

目次

第1章 分析目的・前提条件

第2章 市場概略

  • 分析概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
  • COM (Coherent Opportunity Map:市場機会マップ)

第3章 市場の力学・規制・動向の分析

  • 市場力学
  • 促進要因
  • 抑制要因
  • 影響分析
  • 市場機会
  • 事業提携・企業買収
  • 製品発売
  • パイプライン分析
  • 医療費償還シナリオ
  • 規制シナリオ

第4章 世界のインターフェロンベータ薬市場:COVID-19感染拡大の影響

  • COVID-19以降の影響
  • ソフトジェル生産へのCOVID-19の影響
  • 需給動向の分析
  • 製造業への全体的な影響

第5章 世界のインターフェロンベータ薬市場:製品種類別

  • イントロダクション
    • 市場シェア分析 (最新値・予測値)
    • 対前年成長率 (YoY) の分析 (実績値・予測値)
    • セグメント別動向
  • インターフェロンベータ-1A
    • イントロダクション
    • 市場規模とその予測、対前年成長率 (YoY) (金額ベース)
  • インターフェロンベータ-1B
  • インターフェロンベータ-1A

第6章 世界のインターフェロンベータ薬市場:投与経路別

  • イントロダクション
  • 筋肉内注射 (IM)
  • 皮下注射
  • 静脈内注射 (IV)

第7章 世界のインターフェロンベータ薬市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 世界のインターフェロンベータ薬市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • 他のラテンアメリカ諸国
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • ロシア
    • 他の欧州諸国
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • ASEAN諸国
    • 他のアジア太平洋諸国
  • 中東
    • 湾岸協力会議 (GCC) 諸国
    • イスラエル
    • 他の中東諸国
  • アフリカ
    • 北部アフリカ
    • 中部アフリカ
    • 南部アフリカ

第9章 競合情勢

  • 企業プロファイル
  • Biogen Idec
    • 企業概要
    • 製品/治験ポートフォリオ
    • 近年の主な動向
    • 財務実績
    • 市場戦略
  • Merck KGaA
  • Novartis Pharmaceuticals Corporation
  • Bayer
目次

Title:
Interferon Beta Drugs Market, by Product Type (Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A), by Route of Administration (Intramuscular, Subcutaneous, and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Interferon beta drug is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but slows down progression of some of the disabling effects and decreases the number of relapses of the disease. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized in Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20-50 years. According to the Multiple Sclerosis Foundation, in 2017, this autoimmune condition affects 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Thus, increasing prevalence of multiple sclerosis is a major factor driving the growth of global interferon beta drugs market.

Key features of the study:

  • This report provides in-depth analysis of the global interferon beta drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global interferon beta drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

  • Global Interferon Beta Drugs Market, By Product Type:
    • Interferon Beta-1A
    • Interferon Beta-1B
    • Peginterferon Beta-1A
  • Global Interferon Beta Drugs Market, By Route of Administration:
    • Intramuscular
    • Subcutaneous
    • Intravenous
  • Global Interferon Beta Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interferon Beta Drugs Market, By Region:
    • North America
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Product Type:
      • Interferon Beta-1A
      • Interferon Beta-1B
      • Peginterferon Beta-1A
      • By Route of Administration:
      • Intramuscular
      • Subcutaneous
      • Intravenous
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles:
    • Biogen Idec
    • Merck KGaA
    • Novartis Pharmaceuticals Corporation
    • Bayer
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Drivers
  • Restraints
  • Impact Analysis
  • Market Opportunities
  • Collaboration and acquisition
  • Product Launch
  • Pipeline Analysis
  • Reimbursement Scenario
  • Regulatory Scenario

4. Global Interferon Beta Drugs Market, Impact of COVID-19 Pandemic

  • Post COVID-19 Impact
  • COVID-19 Impact on Softgel Productions
  • Demand and Supply Analysis
  • Overall impact on manufacturing industry

5. Global Interferon Beta Drugs Market, By Product Type, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Interferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Interferon Beta-1B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Peginterferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

6. Global Interferon Beta Drugs Market, By Route of Administration, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

7. Global Interferon Beta Drugs Market, By Distribution Channel, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, 2017-2027
  • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2027, (US$ Mn)

8. Global Interferon Beta Drugs Market, By Region, 2016-2027 (US$ Mn)

  • Introduction
  • Market Share Analysis, By Country, 2020 and 2027 (%)
  • Y-o-Y Growth Analysis, For Countries, 2017-2027
  • North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
  • Introduction
  • Market Size and Forecast, By Product Type, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Application, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2016-2027 (US$ Mn)
  • Market Size and Forecast, By Country, 2016-2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
  • Biogen Idec
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Merck KGaA
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Novartis Pharmaceuticals Corporation
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Bayer
  • Company Overview
  • Clinical Trial Phase Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
  • Market Strategies

Browse 28 market data tables and 30 figures on " Global Interferon Beta Drugs Market - Global forecast to 2027".

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.